These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16222588)
1. [A role for combination therapy in pulmonary arterial hypertension]. Behr J; Borst MM; Winkler J; Hoeper M; Halank M; Ghofrani A; Klose H; Wilkens H; Stähler G Pneumologie; 2005 Oct; 59(10):730-5. PubMed ID: 16222588 [TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
3. [Combination therapy in patients with pulmonary arterial hypertension]. Ewert R; Opitz CF; Schäper C; Gläser S Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093 [TBL] [Abstract][Full Text] [Related]
4. [Drug combination treatment for pulmonary arterial hypertension]. Ghofrani HA; Hoeper MM Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S330-3. PubMed ID: 17139600 [TBL] [Abstract][Full Text] [Related]
5. Combination drug therapy in the management of pulmonary arterial hypertension. Kayser SR Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142 [No Abstract] [Full Text] [Related]
6. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876 [TBL] [Abstract][Full Text] [Related]
7. "Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation. Hoeper MM Eur Respir Rev; 2011 Dec; 20(122):297-300. PubMed ID: 22130824 [No Abstract] [Full Text] [Related]
11. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [TBL] [Abstract][Full Text] [Related]
13. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
14. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL; Michelakis ED Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [TBL] [Abstract][Full Text] [Related]